Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2946 (LINC02946), also known as RMEL1, is a primate-specific long non-coding RNA identified through analysis of melanoma-specific gene expression patterns. It is highly restricted in its expression to melanocytic lineage cells, including normal melanocytes and a significant proportion of melanoma cell lines, with up-regulation in both primary and metastatic tumors but usually absent from other tissues. RMEL1’s expression profile is more exclusive to melanocytic cells than other canonical markers, suggesting potential utility for diagnosis and prognosis in melanoma. While its exact biological function remains to be experimentally clarified, RMEL1’s specificity suggests a possible involvement in melanocyte differentiation, pigmentation, or melanoma progression, and it may be useful in future development of biomarkers or therapeutic strategies for melanoma. No direct drug interactions or mechanistic pharmacological data are available at present.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2946 (LINC02946).